Gemseki

Cellusion Inc. is a Tokyo-based regenerative medicine company specializing in the research and development, manufacturing, and sales of induced pluripotent stem cell-derived corneal endothelial cells aimed at treating bullous keratopathy. Founded in 2015, Cellusion focuses on providing innovative solutions for cell transplantation, utilizing a mass culture system for corneal endothelial cells derived from iPS cells. This approach allows healthcare professionals to improve vision in patients suffering from bullous keratopathy by injecting the cell substitutes, which replace damaged corneal tissue, thereby enhancing the quality of life for affected individuals.

Curreio is a biotechnology company focused on drug discovery through advanced structural analysis using cryo-electron microscopy. The company offers a platform that enables researchers to observe biological structures in their native state by freezing them without staining. This innovative approach facilitates the discovery and analysis of potential life-saving drugs, leveraging structural analysis techniques to enhance the drug development process. By providing cutting-edge technology, Curreio aims to improve the efficiency and effectiveness of drug discovery efforts in the biotechnology sector.

Cardio Intelligence Inc. specializes in the research, development, and sale of artificial intelligence (AI) systems for electrocardiographic diagnosis. Founded in 2019 and based in Tokyo, Japan, the company has created an AI-based diagnostic system that delivers analysis accuracy comparable to that of medical specialists. This system is designed to facilitate early detection of conditions like atrial fibrillation, thereby assisting healthcare professionals in the treatment and prevention of heart diseases. Additionally, Cardio Intelligence offers software development, patent licensing, and contract services for pharmaceutical companies, along with medical equipment lending and repair services. The company aims to improve access to medical care for patients worldwide, particularly those facing difficulties in obtaining timely treatment for heart-related issues.